Plain-English fact sheet
GHK-Cu
Also known as copper tripeptide-1, copper peptide GHK-Cu
GHK-Cu is a naturally occurring copper complex used in some cosmetics, but broad skin repair, hair growth, systemic healing, or anti-aging claims outrun high-quality human evidence.
Quick answer
GHK-Cu is a copper-binding tripeptide studied in skin, wound, and hair biology. It is not an FDA-approved drug for wound healing, hair loss, anti-aging, or systemic use, and evidence depends heavily on formulation and route.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is GHK-Cu?
GHK-Cu is a complex of the three-amino-acid peptide glycyl-L-histidyl-L-lysine with copper.
A topical cosmetic ingredient, an experimental wound product, and an injected compounded product are different exposures with different evidence and risks.
Why are people interested in it?
Laboratory and animal studies report effects on collagen, extracellular matrix, inflammation, and tissue-repair signaling.
It appears in skin-care and hair-growth marketing, where evidence for an ingredient is often stretched into claims about a specific finished product or systemic therapy.
Current regulatory status
No GHK-Cu drug product is FDA approved for wound healing, hair growth, anti-aging, or systemic use. FDA identifies potential immune and impurity risks for compounded injectable GHK-Cu and limited human safety data.
What is it approved for?
No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.
What is it being studied for?
Investigational areas
- Topical skin and wound applications
- Hair-growth and follicle biology
- Tissue-repair signaling
Evidence snapshot
Much of the mechanistic and wound-healing evidence comes from cells or animals. Limited cosmetic research cannot establish broad medical, hair-growth, or systemic anti-aging claims.
Potential benefits being researched
- Animal wound models report increased collagen and extracellular-matrix accumulation.
- Small cosmetic studies and ingredient research suggest possible skin effects, but results are formulation-specific and not equivalent to an approved medical treatment.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- FDA identifies potential immune reactions, aggregation, and peptide-related impurity concerns for compounded injectable GHK-Cu.
- Human systemic safety data are limited, and cosmetic tolerability does not establish safety by another route.
- Copper exposure, formulation ingredients, contamination, and product mislabeling can change risk.
What we still do not know
- Whether any finished product produces clinically meaningful wound or hair outcomes
- Long-term topical and systemic safety across formulations
- Whether laboratory signaling changes translate into visible or functional benefit
- Quality and identity of unapproved products marketed under the name
Plain-English takeaway
GHK-Cu is a plausible cosmetic and wound-research ingredient, not a single proven anti-aging or healing therapy. The finished formulation, route, outcome, and human trial matter.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1FDA: safety risks for selected compounded bulk substances
FDA's current substance-specific summary of evidence gaps and potential safety risks.
- 2GHK-Cu wound study in rats
Animal wound-chamber study showing extracellular-matrix effects; not proof of human clinical benefit.
- 3FDA: 503A bulk-substance status for GHK-Cu
May 2026 FDA status document distinguishing non-injectable evaluation from injectable safety concerns.
- 4FDA: understanding the risks of compounded drugs
FDA overview explaining that compounded drugs are not reviewed before marketing for safety, effectiveness, or quality.